相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2013
已完成
2
66.7%
尚未招募
1
33.3%
暂无批准数据
- Halozyme Therapeutics has elected Dannielle Appelhans to its Board of Directors, bringing more than 20 years of executive leadership across biotechnology and pharmaceuticals. - Ms. Appelhans brings deep expertise in operations, manufacturing, and supply chain management, aligning with Halozyme's growth strategy for its ENHANZE, Hypercon, and Surf Bio platforms. - She currently serves as President and CEO of COUR Pharmaceuticals, where she executed a strategic collaboration with Genentech valued at up to $1 billion. - Her prior leadership includes roles at Novartis Gene Therapies, where she oversaw development, manufacturing, and supply chain for the approved therapy Zolgensma.
- Scarlet Therapeutics demonstrated that its lab-grown universal red blood cells achieve a half-life comparable to normal donated red blood cells in preclinical studies, marking a pivotal validation of the technology. - The company's proprietary immortalized cell line technology enables scalable manufacturing of universal RBCs that can be administered regardless of blood type, removing compatibility constraints. - Scarlet raised £3.2 million in seed funding to advance therapeutic applications targeting metabolic diseases including hyperammonemia and hyperoxaluria. - The platform supports three application areas: therapeutic RBCs for disease treatment, universal transfusion products, and performance-enhancing RBC systems.
